Muscle Disease Biotech Prepares for Clinical Trials, Market Cap Increases by $130 Billion in a Day

EDGEWISE Therapeutics Inc. (NASDAQ: EWTX), a developer of treatments for muscle diseases, closed up 2.82% at $30.64 on the Nasdaq, equivalent to roughly 41,000 Korean won. Trading volume was about 1.3 million shares, and its market capitalization reached approximately $3.29 billion (around 4.4 trillion won), rising by about $95.4 million (roughly 130 billion won) in a single day.

The company plans to present clinical data for its Becker and Duchenne muscular dystrophy treatment, sevasemten, in June 2025 and then launch pivotal trials in 2026. As of the third quarter of 2025, it holds around $560 million in cash and marketable securities, according to its Form 8-K and Form 10-Q filings.

Meanwhile, after the Portnoy Law Firm announced in August that it had opened an investigation over potential investor losses, Edgewise has been boosting its visibility within the muscle disease community by hosting an industry-forum lunch at the Muscular Dystrophy Association’s scientific conference in March 2026.

Edgewise Therapeutics is a clinical-stage biotech developing sevasemten, an oral therapy targeting Becker and Duchenne muscular dystrophy; EDG-7500, a cardiac modulator for hypertrophic cardiomyopathy; and EDG-15400, a heart failure candidate. It has no commercial products on the market.

With all key pipeline programs in clinical development, the company’s share price and valuation are considered highly volatile, driven by individual trial results, regulatory updates, and financing news.